Acne Treatment – Pharmas Online Wed, 23 Nov 2022 03:55:19 +0000 en-US hourly 1 Acne Treatment – Pharmas Online 32 32 Why You Should Add Bee Propolis To Your Skincare Routine Wed, 23 Nov 2022 01:05:00 +0000

Farmacy’s Clean Bee Ultra Gentle Face Wash is a dream for sensitive skin. Made with propolis, aloe vera juice and hyaluronic acid, this cleanser refreshes the skin without stripping it too much. It is moisturizing and easily removes makeup and dirt. According to reviews, the gel cleanser lathers easily and has a pleasant scent, likely due to the lavender and basil in the ingredients.

Known for their snail mucin products, Korean skincare brand Cosrx also offers an amazing range of propolis products. Its Full Fit Propolis Synergy Toner is a soothing and hydrating toner. The toner is made of 72% propolis and 10% honey, providing smooth and glowing skin. It targets dull and dehydrated skin, improves texture and reduces redness. The synergy toner has a rating of 4.9 on the Cosrx website. Reviewers call it their “holy grail”, crediting it with getting rid of acne and dry patches on the skin.

Lather’s Honey Hydrating Mask with Propolis Extract hydrates and soothes skin prone to dryness from weather or pollution. Intended for dry, combination and mature skin, this mask is intended to be used overnight. Containing olive oil, glycerin, aloe vera and rosemary leaf extract, the mask is a savior for dry skin in winter.

Deucravacitinib shows promise for systemic lupus erythematosus in phase 2 trial Sun, 13 Nov 2022 20:33:50 +0000

On the heels of its approval for use in patients with plaque psoriasis, new research from a phase 2 trial provides insight into the effects of the oral tyrosine kinase 2 (TYK2) inhibitor in a population of patients with systemic lupus erythematosus (SLE).

Presented at the American College of Rheumatology (ACR) Convergence 2022, results from the trial, which included more than 360 people from more than 15 countries, demonstrate that deucravacitinib use was associated with higher response rates elevated for the SLE Responder Index 4 (SRI-4) response at week 32 as well as notable improvements in other endpoints over placebo treatment, with the researchers also pointing to an acceptable safety profile for the agent .

“The TYK2 transducer signals a unique set of cytokines highly relevant to SLE,” said corresponding author Eric Morand, MBBS, PhD, of Monash University, in a statement. “These results put TYK2 on the map as a target in lupus and encourage the further development of deucravacitinib in this disease.”

A member of the family of JAK inhibitors that mediate IL-23, IL-12, and type I IFN signaling, deucravacitinib has caught the attention of rheumatologists and rheumatic disease specialists for its potential in the treatment of various chronic conditions as a result of its effect on inflammatory markers. As a result, deucravacitinib has become the focus of research efforts in plaque psoriasis, psoriasis, ulcerative colitis, and, in the present study, SLE.

To examine the agent’s use in SLE, researchers designed the Phase 2 trial as a quadruple masked, randomized, double-blind, placebo-controlled study with the intention of randomizing adult patients with LES in a 1:1:1:1 ratio to receive deucravacitinib 3 mg twice daily, 6 mg twice daily, 12 mg once daily, or placebo.

The primary endpoint of interest for the study was SRI-4 response at week 32. Secondary endpoints of interest, which were assessed at week 48, included SRI-4 response, British Isles Lupus Assessment Group–Based Composite Lupus Lupus Erythematosus Disease Area and Severity Index 50 (CLASI-50), Lupus Low Disease Activity State (LLDAS) and improvement in active, swollen and painful joint counts. The trial also included several safety outcomes of interest, such as the rate of adverse events and the incidence of death or major adverse cardiovascular events.

A total of 363 people were randomized in the study. Of these, 90, 91, 93, and 89 people were randomized to receive placebo, deucravacitinib 3 mg twice daily, deucravacitinib 6 mg twice daily, and deucravacitinib 12 mg once daily, respectively. . Of the 363 included in the study, 75.8% completed the 48 weeks of treatment.

After analysis, the results suggested that the proportion of patients achieving an SRI-4 response was 34% among those receiving placebo treatment, which was lower than the 58% achieved with deucravacitinib 3 mg twice daily (OR, 2.8 [95% CI, 1.5-5.1]; P<.001), 50% achieved with 6 mg twice daily (OR, 1.9 [95% CI, 1.0-3.4]; P= 0.02), and 45% achieved with 12 mg once daily (OR, 1.6 [95% CI, 0.8-2.9]; P=.08). Further analysis indicated that response rates were higher with deucravacitinib treatment for BICLA, CLASI-50, LLDAS and joint count compared to placebo treatment.

In safety analyses, results indicated that rates of adverse events were similar with placebo and deucravacitinib treatment, except for higher rates of infections and skin events including rash and acne, seen with deucravacitinib. Regarding serious adverse events, the results suggest that the rates were comparable between the study arms, with deaths, opportunistic infections, tuberculosis infections, major adverse cardiovascular events or thrombotic events reported in both arms.

This study, “Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial,” was presented at ACR Convergence 22 and simultaneously published in Arthritis and rheumatology.

This $10 Acne Cleansing Bar Has Been Bought 1 Million Times Fri, 11 Nov 2022 17:44:23 +0000

For those of us who struggle with acne, we know how difficult it can be to know which products are legit in the ever-growing skin care and breakout prevention market. Although active ingredients and reliable formulas are often good indicators of whether or not a product will work on problematic or reactive skin, one of the best and most common ways to judge whether or not a product will work for you is to see first-hand testimonials and real results. Luckily, for anyone in need of a proven acne product right now, UK’s number one skincare brand, Carbon Theory, has just announced that its popular cleansing bar has been proven to work in officially reaching one million sales worldwide.

Carbon Theory’s Viral Charcoal & Tea Tree Oil Facial Cleansing Bar ($10) contains organic activated charcoal, organic tea tree oil, and shea butter, which work together to cleanse and nourish the skin . Activated Charcoal gently extracts and removes deep-buried bacteria, excess oil and acne-causing toxins while Organic Tea Tree Oil acts as a natural antiseptic to reduce inflammation and keep skin healthy. healthy skin. The added benefit of shea butter as another main ingredient ensures that the skin is not stripped of natural fatty acids and the face remains hydrated and nourished throughout use.

Not only has Carbon Theory’s best-selling cleansing bar been purchased a million times to date, but the product has also garnered over 13,000 five-star reviews and tons of positive consumer feedback in the form of incredible before and after the real person. Pictures. The best part? At $10, this powerful acne-fighting product is affordable and accessible, sold not only on Carbon Theory’s site, but also at global retailers like Walgreens and Ulta.

Finding products that effectively treat and prevent acne is no small feat, but Carbon Theory’s famous cleansing bar is proof that real results don’t always have to come from expensive luxury products. With natural yet powerful skin-cleansing ingredients and endless positive reviews to support their effectiveness, Carbon Theory’s The Charcoal & Tea Tree Oil Facial Cleansing Bar might just be the handy solution we needed for reactive skin.